PRL and pituitary gland adenoma: Patients with PRL-secreting pituitary adenomas have increased plasma concentrations of dehydroepiandrosterone sulphate (DHEAS) and whilst dopamine agonists reduce both serum PRL and DHEAS concentrations, they do not inhibit adrenocorticotropic releasing hormone secretion (ACTH) [54].